{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:21:49Z","timestamp":1788272509464,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/100015739","name":"Bayer Vital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020957","name":"Roche Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024516","name":"Astellas Pharma Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024516","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Intravitreale operative Medikamenteneingaben (IVOMs) im Versorgungsalltag erreichen h\u00e4ufig nicht die in klinischen Studien gezeigten Behandlungsergebnisse. In Deutschland fehlen bislang fl\u00e4chendeckende, repr\u00e4sentative Real-World-Daten zur IVOM-Versorgung bei Makulaerkrankungen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ziel der Arbeit<\/jats:title>\n                    <jats:p>\n                      Vor diesem Hintergrund wurde das\n                      <jats:italic>oregis-IVOM-Register<\/jats:italic>\n                      als Subregister des nationalen\n                      <jats:italic>oregis-Registers<\/jats:italic>\n                      etabliert. Ziel ist die standardisierte Erhebung und Analyse von IVOM-Therapieverl\u00e4ufen im klinischen Alltag in Deutschland, um Langzeitergebnisse abzubilden und Optimierungspotenziale in der Versorgung zu identifizieren. Teilnehmende augen\u00e4rztliche Zentren k\u00f6nnen durch ihre Beteiligung aktiv zur evidenzbasierten Weiterentwicklung der IVOM-Versorgung beitragen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material und Methoden<\/jats:title>\n                    <jats:p>\n                      Das\n                      <jats:italic>oregis-IVOM-Register<\/jats:italic>\n                      ist eine prospektive, nichtinterventionelle Beobachtungsstudie. Erfasst werden medizinische Versorgungsdaten erwachsener Patienten, die aufgrund einer neovaskul\u00e4ren altersabh\u00e4ngigen Makuladegeneration (nAMD), eines diabetischen Makula\u00f6dems (DM\u00d6), retinaler Venenverschl\u00fcsse (RVV) oder choroidaler Neovaskularisation (CNV) eine IVOM-Therapie erhalten. Die Datenerfassung erfolgt webbasiert mittels Remote Date Entry in einer elektronischen Datenbank \u00fcber REDCap. Struktur, Datens\u00e4tze und Erhebungsparameter orientieren sich am internationalen Fight Retinal Blindness!-Register.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diskussion<\/jats:title>\n                    <jats:p>\n                      Das\n                      <jats:italic>oregis-IVOM-Registe<\/jats:italic>\n                      r bietet erstmals eine nationale, strukturierte Plattform, um reale Behandlungsverl\u00e4ufe systematisch zu erheben und auszuwerten. Es schlie\u00dft eine wichtige Wissensl\u00fccke in der IVOM-Versorgungsforschung in Deutschland und erm\u00f6glicht regionale und internationale Vergleiche sowie Analysen zu Therapieadh\u00e4renz und Versorgungsrealit\u00e4t.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00347-026-02509-6","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:59:32Z","timestamp":1788271172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Das oregis-IVOM-Register\u00a0\u2013 Einf\u00fchrung eines Registers f\u00fcr die systematische Erhebung repr\u00e4sentativer IVOM-Versorgungsdaten aus dem Behandlungsalltag bei Makulaerkrankungen in Deutschland","The oregis IVOM registry\u2014Introduction of a registry for the systematic documentation of representative IVOM treatment data from routine treatment of macular diseases in Germany"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5627-7127","authenticated-orcid":false,"given":"Ildik\u00f3","family":"Pisz\u00e1r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyrios","family":"Chronopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Schloesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Eter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian Alexander","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"oregis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Finger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2509_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-8-18","volume":"8","author":"M Abegg","year":"2008","unstructured":"Abegg\u00a0M, Tappeiner\u00a0C, Wolf-Schnurrbusch\u00a0U, Barthelmes\u00a0D, Wolf\u00a0S, Fleischhauer\u00a0J (2008) Treatment of Branch Retinal Vein Occlusion induced Macular Edema with Bevacizumab. J\u00a0West Afr Coll Surg 8:18. https:\/\/doi.org\/10.1186\/1471-2415-8-18","journal-title":"BMC Ophthalmol"},{"key":"2509_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown\u00a0DM, Michels\u00a0M, Kaiser\u00a0PK, Heier\u00a0JS, Sy\u00a0JP, Ianchulev\u00a0T (2009) Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study. Ophthalmol Sci 116:57\u201365.e5. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.018","journal-title":"Ophthalmology"},{"key":"2509_CR3","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2147\/OPTH.S209253","volume":"13","author":"J Callizo","year":"2019","unstructured":"Callizo\u00a0J, Ziemssen\u00a0F, Bertelmann\u00a0T, Feltgen\u00a0N, V\u00f6geler\u00a0J, Koch\u00a0M, Eter\u00a0N, Liakopoulos\u00a0S, Schmitz-Valckenberg\u00a0S, Spital\u00a0G (2019) Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study. Clin Ophthalmol Auckl NZ 13:2167\u20132179. https:\/\/doi.org\/10.2147\/OPTH.S209253","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"2509_CR4","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"U Chakravarthy","year":"2012","unstructured":"Chakravarthy\u00a0U, Harding\u00a0SP, Rogers\u00a0CA, Downes\u00a0SM, Lotery\u00a0AJ, Wordsworth\u00a0S, Reeves\u00a0BC (2012) Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration. Ophthalmol Sci 119:1399\u20131411. https:\/\/doi.org\/10.1016\/j.ophtha.2012.04.015","journal-title":"Ophthalmology"},{"key":"2509_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/IAE.0b013e318296b271","volume":"34","author":"MC Gillies","year":"2014","unstructured":"Gillies\u00a0MC, Walton\u00a0R, Liong\u00a0J, Arnold\u00a0JJ, McAllister\u00a0I, Morlet\u00a0N, Hunyor\u00a0A, Guymer\u00a0R, Keeffe\u00a0J, Essex\u00a0R, Herrera-Bond\u00a0A, Glastonbury\u00a0B, Simpson\u00a0JM, Barthelmes\u00a0D (2014) EFFICIENT CAPTURE OF HIGH-QUALITY DATA ON OUTCOMES OF TREATMENT FOR MACULAR DISEASES: The Fight Retinal Blindness! Project. Retina 34:188\u2013195. https:\/\/doi.org\/10.1097\/IAE.0b013e318296b271","journal-title":"Retina"},{"key":"2509_CR6","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier\u00a0JS, Brown\u00a0DM, Chong\u00a0V, Korobelnik\u00a0JF, Kaiser\u00a0PK, Nguyen\u00a0QD, Kirchhof\u00a0B, Ho\u00a0A, Ogura\u00a0Y, Yancopoulos\u00a0GD, Stahl\u00a0N, Vitti\u00a0R, Berliner\u00a0AJ, Soo\u00a0Y, Anderesi\u00a0M, Groetzbach\u00a0G, Sommerauer\u00a0B, Sandbrink\u00a0R, Simader\u00a0C, Schmidt-Erfurth\u00a0U (2012) Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmol Sci 119:2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"2509_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz\u00a0FG, Tadayoni\u00a0R, Beatty\u00a0S, Berger\u00a0A, Cereda\u00a0MG, Cortez\u00a0R, Hoyng\u00a0CB, Hykin\u00a0P, Staurenghi\u00a0G, Heldner\u00a0S, Bogumil\u00a0T, Heah\u00a0T, Sivaprasad\u00a0S (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220\u2013226. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305327","journal-title":"Br J Ophthalmol"},{"key":"2509_CR8","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik\u00a0JF, Do\u00a0DV, Schmidt-Erfurth\u00a0U, Boyer\u00a0DS, Holz\u00a0FG, Heier\u00a0JS, Midena\u00a0E, Kaiser\u00a0PK, Terasaki\u00a0H, Marcus\u00a0DM, Nguyen\u00a0QD, Jaffe\u00a0GJ, Slakter\u00a0JS, Simader\u00a0C, Soo\u00a0Y, Schmelter\u00a0T, Yancopoulos\u00a0GD, Stahl\u00a0N, Vitti\u00a0R, Berliner\u00a0AJ, Zeitz\u00a0O, Metzig\u00a0C, Brown\u00a0DM (2014) Intravitreal Aflibercept for Diabetic Macular Edema. Ophthalmol Sci 121:2247\u20132254. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.006","journal-title":"Ophthalmology"},{"key":"2509_CR9","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin\u00a0DF, Maguire\u00a0MG, Fine\u00a0SL, Ying\u00a0G, Jaffe\u00a0GJ, Grunwald\u00a0JE, Toth\u00a0C, Redford\u00a0M, Ferris\u00a0FL (2012) Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration. Ophthalmol Sci 119:1388\u20131398. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053","journal-title":"Ophthalmology"},{"key":"2509_CR10","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld\u00a0PJ, Brown\u00a0DM, Heier\u00a0JS, Boyer\u00a0DS, Kaiser\u00a0PK, Chung\u00a0CY, Kim\u00a0RY (2006) Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"2509_CR11","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","volume":"119","author":"MA Singer","year":"2012","unstructured":"Singer\u00a0MA, Awh\u00a0CC, Sadda\u00a0S, Freeman\u00a0WR, Antoszyk\u00a0AN, Wong\u00a0P, Tuomi\u00a0L (2012) HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Ophthalmol Sci 119:1175\u20131183. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.016","journal-title":"Ophthalmology"},{"key":"2509_CR12","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1055\/a-1083-6417","volume":"82","author":"J Stausberg","year":"2020","unstructured":"Stausberg\u00a0J, Maier\u00a0B, Bestehorn\u00a0K, Gothe\u00a0H, Groene\u00a0O, Jacke\u00a0C, J\u00e4nicke\u00a0M, Kostuj\u00a0T, Mathes\u00a0T, Niemeyer\u00a0A, Olbrich\u00a0K, Schmitt\u00a0J, Neugebauer\u00a0E (2020) Memorandum Register f\u00fcr die Versorgungsforschung: Update 2019. Gesundheitswesen 82:e39\u2013e66. https:\/\/doi.org\/10.1055\/a-1083-6417","journal-title":"Gesundheitswesen"},{"key":"2509_CR13","doi-asserted-by":"publisher","first-page":"e942","DOI":"10.1111\/aos.13771","volume":"96","author":"J Stefanickova","year":"2018","unstructured":"Stefanickova\u00a0J, Cunha-Vaz\u00a0J, Ulbig\u00a0M, Pearce\u00a0I, Fern\u00e1ndez-Vega Sanz\u00a0A, Theodossiadis\u00a0P, Kodjikian\u00a0L, Izmailov\u00a0A, Muston\u00a0D, Vassilev\u00a0Z, Lamotte\u00a0B, T\u00fcckmantel\u00a0C, Friedl\u00a0S, Altemark\u00a0A, Schwarz\u00a0H, Katz\u00a0T (2018) A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS). Acta Ophthalmol Suppl 96:e942\u2013e949. https:\/\/doi.org\/10.1111\/aos.13771","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"2509_CR14","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00347-022-01804-2","volume":"120","author":"JJ Storp","year":"2023","unstructured":"Storp\u00a0JJ, Dicke\u00a0C, B\u00f6hringer\u00a0D, Schargus\u00a0M, Eter\u00a0N (2023) oregis \u2013 Das deutsche ophthalmologische Register. Ophthalmologie 120:717\u2013725. https:\/\/doi.org\/10.1007\/s00347-022-01804-2","journal-title":"Ophthalmol"},{"key":"2509_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00347-021-01454-w","volume":"119","author":"C Wolfram","year":"2022","unstructured":"Wolfram\u00a0C, Schargus\u00a0M (2022) Das Hamburger Register f\u00fcr intravitreale Injektionstherapien (QIVOM). Ophthalmologie 119:280\u2013287. https:\/\/doi.org\/10.1007\/s00347-021-01454-w","journal-title":"Ophthalmol"},{"key":"2509_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00347-024-01986-x","volume":"121","author":"JA Zimmermann","year":"2024","unstructured":"Zimmermann\u00a0JA, Storp\u00a0JJ, Dicke\u00a0C, Leclaire\u00a0MD, Eter\u00a0N (2024) H\u00e4ufigkeit und Wirkstoffverteilung intravitrealer Injektionen in deutschen Zentren 2015 bis 2021 \u2013 eine oregis-Studie. Ophthalmologie 121:196\u2013206. https:\/\/doi.org\/10.1007\/s00347-024-01986-x","journal-title":"Ophthalmol"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02509-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:59:33Z","timestamp":1788271173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-026-02509-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":16,"alternative-id":["2509"],"URL":"https:\/\/doi.org\/10.1007\/s00347-026-02509-6","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.\u00a0Pisz\u00e1r, A.\u00a0Buhl, A.\u00a0Chronopoulos, L.\u00a0Schloesser, C.\u00a0Dicke, N.\u00a0Eter, J.A.\u00a0Zimmermann,\n                      oregis\n                      und R.P.\u00a0Finger geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}